BMS launches selective cardiac myosin inhibitor drug in India

[ad_1] Bristol Myers Squibb (BMS) has expanded its therapeutic offerings in India into cardiology with the launch of selective cardiac myosin inhibitor Kopozgo (Mavacamten). The development builds on the company’s strong presence in oncology and haematology, BMS said in a release on launch of the drug for treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy […]

Continue Reading

Bristol-Myers Squibb to set up $100 million S&T Innovation Centre in Hyderabad

[ad_1] Industries and IT Minister K.T.Rama Rao, BMS Executive V-P Samit Hirawat with officials of State government and the company in Hyderabad on February 23.   | Photo Credit: Special Arrangement Bristol-Myers Squibb has decided to set up a science and technology innovation centre with an investment of $100 million in Hyderabad to expand its […]

Continue Reading